Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges - Test2 - elhamkhani - TriplyDB

Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges

Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges

http://www.wikidata.org/entity/Q26862516

about

Emerging targeted therapies for glioma.Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.Epidermal growth factor receptor targeting and challenges in glioblastoma.Relationship Between Cytogenetic Complexity and Peritumoral Edema in High-Grade Astrocytoma Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes.Disabled cell density sensing leads to dysregulated cholesterol synthesis in glioblastoma.ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.Molecular targets in glioblastoma.Glioblastoma antigen discovery--foundations for immunotherapy.Molecular profiling of gliomas: potential therapeutic implications.Emerging circulating biomarkers in glioblastoma: promises and challenges.Glioblastoma targeted therapy: updated approaches from recent biological insights.The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.The Effect of Molecular Diagnostics on the Treatment of Glioma.Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro.Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity.Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.EGFRvIII: the promiscuous mutation Targeting OSMR in glioma stem cells.Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges.Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma.COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor.Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.An EGFRvIII targeted dual-modal gold nanoprobe for imaging-guided brain tumor surgery.The Influence of EGFR Inactivation on the Radiation Response in High Grade Glioma.Development and Biological Evaluation of a Photoactivatable Small Molecule Microtubule-Targeting Agent.Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways.What are the prospects for combination therapy for glioblastoma?Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance.The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma

P2860

Q30241853-030E0F26-D14F-4298-81C9-4CDC45088029 Q35763725-54842139-B7F5-4892-967A-38370964E075 Q36759183-F65CD0EA-545C-44D6-8D7A-BB097EE3B006 Q36977684-105982CF-CD35-449F-B305-BDCA7906B65D Q37231526-46E17737-90EA-423A-9B91-634EA7E03069 Q37362563-657487C1-88A7-4DCA-98F5-94D0BD2CCF8D Q37716459-1379DC4C-738F-491F-A2D8-69E0D22A5836 Q38398440-22BE9F11-85B0-4D9F-A41D-482FE1B85EE7 Q38465854-E5824953-5706-4B2A-85F0-BAEBDCDE7AAA Q38516823-8D52F361-399E-4E16-B2A2-44E93CAE0C69 Q38539422-712A6764-D3B7-494E-BABB-EB3053085CC4 Q38591062-C079A460-BC63-420C-8FD9-C4AD54DB442A Q38597700-80AE9B6A-5F76-4BD6-8D13-81D40D5090DA Q38670567-EAC69B7E-84DE-42D0-B080-61F362C8318A Q38743781-B742E243-E555-4804-A9E2-CEADF1889046 Q38778367-AA8512D7-B685-42BC-B89C-A930681C01C1 Q38849515-667AE26D-B825-4F35-AFA7-3FFFBC2CAD50 Q39818316-12FB35E3-B36C-49C4-816F-1FC1BC66A69F Q40116157-74D53988-FE14-4DF3-ABC9-DC4F413B4350 Q40178043-07D0DBE6-2CC8-48AA-BD05-9A63440BA34D Q42367951-B7B1D486-87B3-4ACA-9714-558EC53D536F Q42371304-69DC6113-40D1-403C-B79C-8FF7F6B57E04 Q43376098-946DDFE6-01B2-4598-84DD-390258DBCEA4 Q46311981-F44B128E-5635-4523-B89D-1CAEE701F9A3 Q46353205-12AE454C-5B1D-4514-8548-7642341C4860 Q47130146-694E615B-165F-4FB3-8246-E8FF994327CD Q48014727-82880E70-A18A-45E1-A663-46B12363BE72 Q48552600-83EFD4AA-57FE-4F74-BA00-70481313C334 Q49703767-0D75ECAE-5DC5-45DE-A386-24502F0F304B Q50706838-FF247E2A-B4AC-49B4-B844-9D673B4CCC9F Q52365121-4CCB208E-C415-4486-A039-0DC368723CD5 Q52590668-D304BEEE-8568-44C0-81EA-98B2079B63BF Q54332453-814A575A-B17C-472B-9002-62E91D5D94A4 Q55663256-3DAAB710-9D96-4425-A2D2-03B4CD44C435 Q58611807-B2F253EA-FB11-4653-8233-393B0042479C

P2860

Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges

http://www.wikidata.org/entity/Q26862516

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Targeted molecular therapies a ...... ast experiences and challenges

@ast

Targeted molecular therapies a ...... ast experiences and challenges

@en

Targeted molecular therapies a ...... ast experiences and challenges

@nl

type

label

Targeted molecular therapies a ...... ast experiences and challenges

@ast

Targeted molecular therapies a ...... ast experiences and challenges

@en

Targeted molecular therapies a ...... ast experiences and challenges

@nl

prefLabel

Targeted molecular therapies a ...... ast experiences and challenges

@ast

Targeted molecular therapies a ...... ast experiences and challenges

@en

Targeted molecular therapies a ...... ast experiences and challenges

@nl

P1433

Q26862516-E2297027-355C-4182-A57E-65D3C06F1F78

P1476

Q26862516-BA8E9557-F16D-41EA-BA7B-0DF01119CBB3

P2093

Q26862516-D8CCDFCF-E5F1-4B52-8066-2892E19219A2

Q26862516-DCECAD6C-173E-4AE8-84B5-2B130CCB47E9

Q26862516-E7914FF3-07D0-4408-8590-039C2F054F9B

P2860

Q26862516-026E2FD6-1A8A-4C0B-82F9-69BD7422B4F5

Q26862516-05BE8B97-DF7C-420E-9A7D-C5926657D08E

Q26862516-0B5C3332-7997-405D-A293-AE92026FF5D2

Q26862516-0C69AA95-9BF3-4A32-AE9B-A366750ACC95

Q26862516-17CBF40B-2D6F-4DDD-BD52-464BA971E8BA

Q26862516-1847E340-B931-499B-9E94-C91F35724645

Q26862516-194B00DC-D042-41E1-A743-F00A9934E07D

Q26862516-1ADCC33F-FF33-47E1-A7D7-26B32EC22D9D

Q26862516-1D428E94-B4EA-4102-A255-77391CCEE37D

Q26862516-1EB0EA24-8A69-4FD7-AAB3-F2831E20ED2B

P304

Q26862516-04A842BF-347A-4BA2-9DD7-F266C6DBEA01

P31

Q26862516-6BE3FE7B-B4D8-4C89-B894-1E2B911F7B82

P3181

Q26862516-7E000005-FA17-4B46-8C15-04C150DA4504

P356

Q26862516-7C448948-9029-4FF8-A0BA-49CEB67F6542

P407

Q26862516-651CAB56-2197-4EDA-8396-19037323FF93

P478

Q26862516-8D3F92BE-8BD0-48E0-9884-9A33A0B7D955

P577

Q26862516-0E339872-F139-47E5-9E0C-4EF491271543

P698

Q26862516-4514FB5C-10CC-4B50-A1CA-66B166EA6A5B

P932

Q26862516-CEBB163C-DB20-4B58-93CC-621C30ED6C6A

P3181

P356

P1433

P1476

Targeted molecular therapies a ...... ast experiences and challenges

@en

P2093

D. A. Reardon

http://www.w3.org/2001/XMLSchema#string

I. K. Mellinghoff

http://www.w3.org/2001/XMLSchema#string

P. Y. Wen

http://www.w3.org/2001/XMLSchema#string

P2860

IDH1 and IDH2 mutations in gliomas

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

P304

viii7-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2082286

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/NEUONC/NOU232

http://www.w3.org/2001/XMLSchema#string

P407

P478

16 Suppl 8

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25342602

http://www.w3.org/2001/XMLSchema#string

P932

4207137

http://www.w3.org/2001/XMLSchema#string